RLYB

About Rallybio Corporation Common Stock (RLYB) Stock

Rallybio Corporation Common Stock (RLYB) closed the 2026-09-16 session at $16.98, down 1.39% versus the previous close (-0.24). The stock opened at $17.24 and traded between $16.94 and $17.24 during that session. Session trading volume was 5K shares. The volume-weighted average price (VWAP) is $17.05.

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Rallybio Corporation Common Stock has a market capitalization of $91.4 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RLYB is listed on the XNAS exchange. The company employs approximately 7 people. Rallybio Corporation Common Stock is headquartered in NEW HAVEN, CT. The recorded listing date is 2021-07-29.

On this page you can find market RLYB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.